The current study data provide evidence that treating patients with inflammatory diseases, such as CD or juvenile idiopathic arthritis (JIA), early after diagnosis with TNF-α inhibitors prevents not only disease progression, but also the loss of structural functioning and other disease complications [60,67]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.